Aditxt (ADTX) Competitors

Aditxt (NASDAQ:ADTX) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.

Is ADTX or ARTL more profitable?

Artelo Biosciences' return on equity of -104.59% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	N/A	-439.07%	-122.96%
Artelo Biosciences	N/A	-104.59%	-94.06%

Which has more volatility and risk, ADTX or ARTL?

Aditxt has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

Does the media prefer ADTX or ARTL?

In the previous week, Aditxt had 3 more articles in the media than Artelo Biosciences. MarketBeat recorded 4 mentions for Aditxt and 1 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.20 beat Aditxt's score of 0.16 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aditxt	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of ADTX or ARTL?

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 0.8% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor ADTX or ARTL?

Artelo Biosciences received 42 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 76.67% of users gave Artelo Biosciences an outperform vote while only 44.44% of users gave Aditxt an outperform vote.

Company	Underperform	Outperform
Aditxt	Outperform Votes 4 44.44%	Underperform Votes 5 55.56%
Artelo Biosciences	Outperform Votes 46 76.67%	Underperform Votes 14 23.33%

Which has stronger valuation and earnings, ADTX or ARTL?

Artelo Biosciences has lower revenue, but higher earnings than Aditxt.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$640K	2.03	-$32.38M	N/A	N/A
Artelo Biosciences	N/A	N/A	-$9.29M	-$2.87	-0.40

Do analysts prefer ADTX or ARTL?

Artelo Biosciences has a consensus price target of $5.50, suggesting a potential upside of 374.14%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Aditxt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.50

Summary

Artelo Biosciences beats Aditxt on 12 of the 15 factors compared between the two stocks.